Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
No 483s were issued
June 10, 2019
By: Tim Wright
China-based Asymchem, a leading manufacturer of intermediates and active pharmaceutical ingredients (APIs) for the pharmaceutical industry, said that its Dunhua 1 site, a small molecule custom manufacturing API facility, successfully completed a U.S. Food and Drug Administration (FDA) general GMP re-inspection conducted between April 8-12, 2019. The EIR states the inspection outcome as closed, and classified with a “VAI” status (Voluntary Action Indicated). The previous inspection of Dunhua 1 took place in 2017 with no 483 issued. Jilin Asymchem Laboratories, Co., Ltd. (Dunhua 1 site), established in 2007, manufactures APIs and API intermediates for the global pharma industry. “I am grateful yet again for the successful inspection by the FDA,” said Hao Hong, chairman and chief executive officer, Asymchem Group. “This is the second successful inspection for the Dunhua 1 site, and 13th successful western agency audit in total across all Asymchem’s seven manufacturing sites. We are committed to continue enhancing existing quality systems for unyielding quality standards in the manufacturing of GMP products.” Asymchem is a full-service CMC CDMO of APIs for the global pharmaceutical industry. Capabilities include dedicated HPAPI, in-house enzyme evolution and fermentation for biotransformations, end-to-end continuous flow development and application, hydrogenation, cryogenic capabilities, dedicated carbapenem manufacture, and others. Founded in 1997, Asymchem employs 3,320 personnel within China over 7 manufacturing sites. The company has been inspected by regulatory authorities from U.S., China, Australia and South Korea.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !